Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 3/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.32 |
| ▸ | RET | P07949 | 3/20 | 0.32 |
| ▸ | ABL1 | P00519 | 2/20 | 0.32 |
| ▸ | KDR | P35968 | 2/20 | 0.32 |
| ▸ | CDK7 | P50613 | 2/20 | 0.32 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.32 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.32 |
| ▸ | ATR | Q13535 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30988525 | 1.00 | MAPK1 (0.46) | MAPK1DYRK1AHTTKMT2AJAK2 | |
| SCHEMBL3954043 | 0.78 | MAPK1 (0.44) | MAPK1DYRK1APDPK1RETABL1 | |
| SCHEMBL19743465 | 0.78 | MAPK1 (0.53) | MAPK1DYRK1ARETABL1KDR | |
| SCHEMBL12467739 | 0.78 | DYRK1A (0.37) | MAPK1DYRK1APDPK1 | |
| SCHEMBL16946863 | 0.78 | DYRK1A (0.37) | DYRK1AKMT2APDPK1AURKBAURKA | |
| SCHEMBL14331928 | 0.71 | MAPK1 (0.62) | MAPK1DYRK1AHTTKMT2APDPK1 | |
| SCHEMBL14763598 | 0.70 | DYRK1A (0.38) | MAPK1DYRK1AJAK2PDPK1RET | |
| SCHEMBL30180924 | 0.70 | DYRK1A (0.38) | MAPK1DYRK1AJAK2PDPK1RET | |
| SCHEMBL30508312 | 0.68 | DYRK1A (0.55) | DYRK1AHTTKMT2AJAK2PDPK1 | |
| SCHEMBL1585071 | 0.68 | DYRK1A (0.55) | DYRK1AHTTKMT2AJAK2PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294524-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2024-09-05 | — | — | US | disclosed |
| EP-4387965-A2 | ARYL SULFONYL COMPOUNDS AS CCR6 INHIBITORS | ChemoCentryx, Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| US-12012403-B2 | Aryl sulfonyl compounds as CCR6 inhibitors | CHEMOCENTRYX, INC. (US) | 2024-06-18 | — | — | US | disclosed |
| CN-118019735-A | Arylsulfonyl compounds as CCR6 inhibitors | 坎莫森特里克斯公司 | 2024-05-10 | — | — | CN | disclosed |
| EP-3466929-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | MILLENNIUM PHARM INC (US) | 2023-09-06 | — | — | EP | disclosed |
| EP-3466929-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | MILLENNIUM PHARM INC (US) | 2023-09-06 | — | — | EP | disclosed |
| US-20230125684-A1 | Aryl Sulfonyl Compounds as CCR6 Inhibitors | CHEMOCENTRYX, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230113598-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | BIOGEN IDEC MA INC. | 2023-04-13 | — | — | US | disclosed |
| WO-2023023534-A2 | ARYL SULFONYL COMPOUNDS AS CCR6 INHIBITORS | CHEMOCENTRYX, INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| US-20210070752-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | VIRACTA THERAPEUTICS, INC. | 2021-03-11 | — | — | US | disclosed |
| EP-3070077-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2016-09-21 | — | — | EP | disclosed |
| EP-3070077-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2016-09-21 | — | — | EP | disclosed |
| EP-2485731-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | MILLENNIUM PHARM INC (US) | 2016-05-11 | — | — | EP | disclosed |
| EP-2485731-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | MILLENNIUM PHARM INC (US) | 2016-05-11 | — | — | EP | disclosed |
| US-20120208819-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2012-08-16 | — | — | US | disclosed |
| US-20120208819-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2012-08-16 | — | — | US | disclosed |
| US-20120208819-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2012-08-16 | — | — | US | disclosed |
| EP-2485731-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2012-08-15 | — | — | EP | disclosed |
| WO-2011044157-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | BIOGEN IDEC MA INC. (US) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011044157-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | BIOGEN IDEC MA INC. (US) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208819-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | PDK1, PDK2, PDK3 | MAPK1 382/4885DYRK1A 1795/4885HTT 2830/4885 |
| US-20240294524-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | PDK1, PDK2, PDK3 | MAPK1 382/4885DYRK1A 1795/4885HTT 2830/4885 |
| US-12012403-B2 | Aryl sulfonyl compounds as CCR6 inhibitors | CCR6, CCR1, CCR3 | MAPK1 1686/4885DYRK1A 4791/4885HTT 3295/4885 |
| US-20230125684-A1 | Aryl Sulfonyl Compounds as CCR6 Inhibitors | CCR6, CCR1, CCR3 | MAPK1 1686/4885DYRK1A 4791/4885HTT 3295/4885 |
| US-20210070752-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | PDK1, PDK2, PDK3 | MAPK1 382/4885DYRK1A 1795/4885HTT 2830/4885 |
| US-20230113598-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | PDK1, PDK2, PDK3 | MAPK1 382/4885DYRK1A 1795/4885HTT 2830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.